Q&A with Candriam’s Thomson: A science-led, transparent regulatory process is key for biotech sector
Cuts to US FDA funding are fuelling fears of delays to drug approvals that could kickstart a biotech stock selloff
Cuts to US FDA funding are fuelling fears of delays to drug approvals that could kickstart a biotech stock selloff
RLAM’s Ashley Hamilton Claxton highlights five reasons to stay positive about sustainable investment
Technological innovation is ushering in a new era of medicine, writes Rahul Bhushan
Targeting funding of €1.8m in 2025, up from €1.6m in 2024
The firm will donate half of its management fees from its Government Money Market fund
As AMR is considered a leading threat to global health and the economy
‘New government has the chance to tackle these issues’, according to Business & Human Rights Resource Centre
Oxford University’s Ana Nacvalovaite says sovereign wealth funds will ’embrace a more nuanced approach’ to ESG
Vontobel’s Joanna Frontczak is an analyst on the firm’s global impact equities fund
Funds from Alliance Bernstein and Redwheel have been introduced to the managed portfolio service
Huge information gaps remain, said TAM’s Babington as he calls on governments to improve education and access
Pressure is on McDonald’s to reduce the use of antibiotics in its meat production